Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
AssigneeGalectin Therapeutics, Inc.
InventorsPeter G. Traber, Eliezer Zomer, Anatole A. Klyosov
Life of this patent
Estimating the term…
Abstract
Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.
Claims44
(canceled)
A method comprising the steps of:
- obtaining a composition for parenteral or enteral administration comprising a galacto-rhamnogalacturonate in an acceptable pharmaceutical carrier wherein the galacto-rhamnogalacturonate is a galactoarabino-rhamnogalacturonate, comprising a 1,4-linked galacturonic acid (GalA) and methyl galacturonate (MeGalA) residues backbone linked to branched heteropolymers of alternating oligomers of α-1,2 linked rhamnose and α-1,4-linked GalA residues, the rhamnose residues carrying a primary branching of oligomers of 1,4-β-D-galactose residues, 1,5-α-L-arabinose residues, or combinations thereof;
- administering to a subject in need thereof an effective dose of the composition that results in at least one of the following:
- reduction of at least 10% of the expression of iNOS in a disease affected tissue wherein the subject has at a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.
(canceled)
(canceled)
(canceled)
Use of a galacto-rhamnogalacturonate compound in the manufacture of a pharmaceutical composition for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases, wherein the galacto-rhamnogalacturonate is a galactoarabino-rhamnogalacturonate, comprising a 1,4-linked galacturonic acid (GalA) and methyl galacturonate (MeGalA) residues backbone linked to branched heteropolymers of alternating oligomers of α-1,2 linked rhamnose and α-1,4-linked GalA residues, the rhamnose residues carrying a primary branching of oligomers of 1,4-β-D-galactose residues, 1,5-α-L-arabinose residues, or combinations thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An admixture having a galacto-rhamnogalacturonate and a therapeutic agent for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases, wherein the galacto-rhamnogalacturonate is a galactoarabino-rhamnogalacturonate, comprising a 1,4-linked galacturonic acid (GalA) and methyl galacturonate (MeGalA) residues backbone linked to branched heteropolymers of alternating oligomers of α-1,2 linked rhamnose and α-1,4-linked GalA residues, the rhamnose residues carrying a primary branching of oligomers of 1,4-β-D-galactose residues, 1,5-α-L-arabinose residues, or combinations thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.